SCHEMBL3638569

SCHEMBL3638569

CC(C)(C)c1n[nH]cc1CNc1ccc(OCc2ccc(F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.49
MAPT P10636 4/20 0.46
LMNA P02545 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 3/20 0.46
BLM P54132 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
THRB P10828 1/20 0.46
PKM P14618 1/20 0.46
RECQL P46063 1/20 0.46
RAB9A P51151 1/20 0.46
CASP6 P55212 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PPARA Q07869 5/20 0.46
GAA P10253 2/20 0.43
TP53 P04637 1/20 0.43
ATM Q13315 1/20 0.43
CACNA1B Q00975 1/20 0.43
F2 P00734 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3640664 0.88 MAPT (0.54) MAOBMAPTLMNAMEN1KMT2A
SCHEMBL3636895 0.88 LMNA (0.40) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL3641121 0.87 CACNA1B (0.44) MAOBLMNACACNA1B
SCHEMBL3636301 0.82 MAPT (0.48) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL3634675 0.80 MAPT (0.40) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3633546 0.80 MAPT (0.40) MAPTMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3637131 0.79 GAA (0.47) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL3635946 0.79 MAPT (0.38) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL3636356 0.79 KDM4E (0.41) MAOBMAPTMEN1KMT2AALDH1A1
SCHEMBL3636668 0.79 MAPT (0.58) MAOBMAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 MAOB 878/4885MAPT 572/4885LMNA 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.